KIORA PHARMACEUTICALS INC current report, Q2 FY2025

Kiora Pharmaceuticals Inc. Form 8-K Summary

Business Context and Reporting Period

This Form 8-K reports on the Annual Meeting of Stockholders held by Kiora Pharmaceuticals Inc. on June 4, 2025. The company is incorporated in Delaware and its common stock trades on the NASDAQ under the symbol KPRX.

Key Financial Metrics

The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance voting results.

Material Changes and Voting Results

Stockholders voted on three proposals at the Annual Meeting:

  • Proposal 1 (Election of Directors): Carmine Stengone and Brian M. Strem, Ph.D. were elected as Class I Directors for a three-year term.
  • Proposal 2 (Executive Compensation): The compensation of named executive officers was approved on a non-binding advisory basis.
  • Proposal 3 (Auditor Ratification): The appointment of Haskell & White LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2025, was ratified.
Proposal Votes For Votes Against/Withheld Abstained Broker Non-Votes
Election of Directors (C. Stengone) 1,155,217 80,548 (Withheld) N/A 411,877
Election of Directors (B. Strem) 1,156,954 78,811 (Withheld) N/A 411,877
Executive Compensation 1,144,829 82,389 8,547 411,877
Auditor Ratification 1,567,427 78,598 1,617 0

Guidance, Outlook, and Risks

The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items.

Investor Verification Checklist

  • Verify the terms of the newly elected directors (Carmine Stengone and Brian M. Strem) and their tenure until 2028.
  • Review the definitive proxy statement for details on the approved executive compensation package.
  • Confirm the engagement of Haskell & White LLP for the 2025 fiscal year audit.
  • Note the significant number of broker non-votes (411,877) on the director and compensation proposals.